ANI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ANI Pharmaceuticals, Inc.
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.
Medline will pay $286m in cash for Teleflex's oxygen and aerosol therapy, active humidification, and non-invasive ventilation devices as well as incentive spirometers. Those businesses yielded $139m in 2020 revenues, but do not fit into Teleflex's plan for the future.
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- Other Names / Subsidiaries
- BioSante Pharmaceuticals, Inc.
- Cell Genesys, Inc.